High triglycerides, bilirubin, ascorbic acid interference
Outdated/improperly stored strips
Insufficient blood sample volume
Cold environment (<10°C) — relevant in GCC A/C settings
📊HbA1c Interpretation — 3-Month Glycaemic Average
<48 Normal
48–57 Pre-DM
≥58 Diabetes
HbA1c (mmol/mol)
HbA1c (%)
Category / Target
<48
<6.5%
Non-diabetic
48–57
6.5–7.4%
Prediabetes / Borderline
≥48 (target)
≥6.5%
T2DM most patients — individualised
≥53 (target)
≥7.0%
T1DM — NICE target
<53 ideally
<7.0%
Pregnancy (T1/T2DM) — strict
58–64 acceptable
7.5–8.0%
Frail elderly / hypo risk / limited life expectancy
🔑
HbA1c is unreliable in haemolytic anaemia, haemoglobinopathies (sickle cell/thalassaemia — common in GCC), recent blood transfusion, iron deficiency anaemia, and pregnancy. Use fructosamine or CGM TIR instead.
📡Continuous Glucose Monitoring (CGM)
Common CGM Devices
FreeStyle Libre (Abbott) — Flash CGM; scanning required (Libre 2 has alarms); widely available in GCC
Avoid waistbands, scar tissue, areas with lipohypertrophy
Rotate sites every 10–14 days (sensor-specific)
Time in Range (TIR) Targets
70–180 mg/dL
Target range (3.9–10.0 mmol/L)
Population
TIR Target
T1DM / T2DM general
>70% time
Pregnancy (T1DM)
>70% (63–140 mg/dL)
Elderly / High hypo risk
>50% acceptable
Time below range <3.9
<4% (T1DM <1%)
Time above range >10.0
<25%
CGM Alerts & Calibration
Libre 2 / Dexcom — configure low alert at 3.9 mmol/L, urgent low at 3.0
Dexcom G6 — no fingerstick calibration needed; G7 same
CGM reads interstitial fluid — 5–15 min lag behind blood glucose
Always confirm hypoglycaemia with fingerstick before IV treatment
Inpatient Glycaemic Targets
6–10 mmol/L
ICU Target (TGC evidence)
6–10 mmol/L
Surgical Ward
6–12 mmol/L
General Medical Ward
⚠️
TGC Trial (NICE-SUGAR): Targeting 4.5–6.0 mmol/L (tight glycaemic control) in ICU increased mortality due to severe hypoglycaemia events. Current consensus: 6–10 mmol/L in ICU is safer.
🕐Monitoring Frequency Inpatient
Situation
Frequency
Standard diabetic on ward
QID (pre-meals + bedtime)
On VRIII (insulin infusion)
1–2 hourly
DKA / HHS
Hourly (or per protocol)
Post-op — first 24h
2 hourly
Stable, diet-controlled T2DM
Once or twice daily
Nocturnal concern
Add 2–3 am check
📈Stress Hyperglycaemia (Non-Diabetic)
Blood glucose >7.8 mmol/L in a patient without known diabetes during hospital admission.
🔴
Stress hyperglycaemia is independently associated with increased mortality, infections, longer ICU stay, and poor wound healing — treat with same targets as diabetic inpatients.
Action
BG persistently >12: notify medical team; consider VRIII
New diabetes diagnosis: HbA1c on admission, diabetes team referral
Post-discharge follow-up: recheck fasting glucose at 6–8 weeks
Diabetic patient NBM (nil by mouth) for >1 missed meal
Perioperative period — major surgery
Acute illness with poor oral intake / vomiting
DKA / HHS recovery (transitioning off fixed-rate)
BG >20 mmol/L unresponsive to subcutaneous insulin
Patients on total parenteral nutrition (TPN)
Substrate Solution (MUST run concurrently)
💧
10% Glucose + 0.18% NaCl + 20 mmol KCl @ 125 mL/hr Prevents hypoglycaemia and hypokalaemia during insulin infusion.
🚫
Never run insulin infusion without substrate solution. Monitor K⁺ every 4–6 hours.
Standard VRIII Rate Scale (Actrapid)
BG (mmol/L)
Scale 1 (units/hr)
Scale 2 (units/hr)
Scale 3 (units/hr)
<4.0
STOP — treat hypo — recheck 15 min
4.1–6.0
0.5
1
2
6.1–8.0
1
2
4
8.1–10.0
2
4
6
10.1–12.0
3
6
8
12.1–14.0
4
8
10
14.1–20.0
6
10
14
>20
6 + call MD
12 + call MD
16 + call MD
Scale selection: Start Scale 1. Move to Scale 2 if not in target after 2 hours. Scale 3 for insulin-resistant patients (T2DM on large doses, steroids, TPN).
Transitioning Off VRIII
Patient eating — give SC rapid-acting insulin 30 min BEFORE first meal
Continue VRIII for 30–60 min after first SC dose (overlap)
Restart home long-acting insulin same day
💊DKA — Key Inpatient Points
Diagnostic Criteria
BG >11 mmol/L (or known T1DM)
Ketones ≥3 mmol/L (blood) or 2+ (urine)
pH <7.3 / bicarbonate <15 mmol/L
Fixed-Rate Insulin Infusion (FRII)
0.1 units/kg/hr — fixed, not variable
Once BG <14: add 10% glucose alongside 0.9% NaCl
Continue FRII until ketones <0.6 AND pH >7.3
Monitoring in DKA
Blood glucose: hourly
Blood ketones: 1–2 hourly
Venous blood gas: 2 hourly × first 6h
U&E: 2–4 hourly (K⁺ critical)
Fluid balance: hourly urine output
⚠️
Potassium replacement is mandatory if K⁺ <5.5 mmol/L before starting insulin in DKA.
HIGH ALERT MEDICATION: Insulin is a leading cause of medication errors. Always double-check dose, type, time, and route with a second nurse. Never abbreviate "units" — write in full to avoid 10-fold dosing errors.
🎯Injection Technique
Rotation Sites
Site
Absorption Speed
Notes
Abdomen
Fastest
Avoid 5 cm around navel
Upper arm (lateral)
Moderate
May need skin fold in lean patients
Anterior/lateral thigh
Slower
Good for basal insulins
Upper buttock
Slowest
Difficult self-injection; often used in children
Angle of Injection
4–5 mm needle: 90° without skin fold
6–8 mm needle: 90° with skin fold OR 45° without
Pen needle standard: 4–6 mm (BD Nano, NovoFine Plus)
Release skin fold before withdrawing needle
Hold needle in for 10 seconds after full dose delivery
Pen Priming
Prime 2 units into air with each new needle
Confirms needle patency and removes air bubbles
Change needle with each injection (re-use = lipohypertrophy)
❄️Insulin Storage
Full Storage & Handling Guidance (GCC Climate)▶
Status
Storage
Duration
Unopened vial/pen
Fridge 2–8°C
Until expiry
Opened pen (in use)
Room temp ≤28°C
28–30 days (check SPC)
Opened vial
Fridge or ≤25°C
28 days
Tresiba (degludec)
Room temp ≤30°C
8 weeks opened
🔴
GCC DANGER: Car interiors in Saudi Arabia, UAE, Qatar can reach 60–80°C in summer. NEVER store insulin in a car, direct sunlight, or near air conditioning vents (freezing). Both extremes denature insulin protein.
Recognising Damaged Insulin
Cloudy when should be clear (glargine, detemir, rapid analogues)
Clumped or frosted particles after rolling
Colour change — any discolouration = discard
NPH/premixed: if does not resuspend with rolling = discard
Any insulin that has been frozen = discard
Patient Education Points
Use insulated wallet (FRIO® cooling wallet) in GCC heat
Airport security: carry insulin in hand luggage only
Mark date opened on every pen
Do not store near freezer compartment in fridge
Lipohypertrophy
Fatty lumps from repeated injections at same site → unpredictable absorption → erratic BG control. Screen at every diabetes review. Rotate sites systematically within each anatomical area.
⚠️
If switching from lipohypertrophic to healthy tissue: reduce insulin dose by 20–40% initially — absorption will be significantly faster.
Hypoglycaemia unawareness: Loss of adrenergic warning symptoms — common after years of T1DM or with strict BG control. Relaxed HbA1c target (58–64 mmol/mol) + CGM with alarms recommended.
⚡Rule of 15 — Conscious Patient
✅
15g fast-acting carbohydrate → wait 15 minutes → recheck BG → repeat if still <4.0 mmol/L
15g Fast-Acting Carbohydrate Options
Option
Amount
Glucose tablets (GlucoTabs®)
3–4 tablets
Fruit juice (orange/apple)
150–200 mL
Regular (non-diet) soft drink
150 mL
Jelly Babies
5 sweets
Glucogel / Dextrogel
1–2 tubes (buccal)
Sugar (granulated)
3 teaspoons
⚠️
After BG recovers to >4 mmol/L, give long-acting carbohydrate (biscuits/sandwich/next meal) to prevent rebound hypo — especially with sulphonylurea or long-acting insulin.
🏥Unconscious / Unable to Swallow — Emergency Treatment
IV Dextrose (First Choice Inpatient)
Preparation
Volume
Notes
20% dextrose
75 mL IV
Preferred — less osmotic damage
10% dextrose
150 mL IV
Alternative
50% dextrose
AVOID
Tissue necrosis risk — extravasation danger
Give via large bore cannula / large peripheral vein
Recheck BG 15 minutes after IV dextrose
Repeat dose if BG remains <4 mmol/L
IM Glucagon (Community / No IV Access)
Dose: 1 mg IM (GlucaGen® HypoKit or Baqsimi nasal 3 mg)
Hydrate well between Iftar and Suhoor — dehydration worsens hyperglycaemia
CGM: excellent tool during Ramadan to minimise fingerstick burden
ℹ️
GCC nurses should be expert in Ramadan diabetes management — this is a core clinical competency across DHA, DOH, SCFHS, and QCHP curricula given the region's Muslim-majority population.
💊Steroid-Induced Hyperglycaemia
⚠️
Steroids (prednisolone, dexamethasone) cause post-prandial hyperglycaemia — peak glucose typically in the afternoon/evening (BG may be normal fasting).
Mechanism
Increased hepatic glucose production
Peripheral insulin resistance
Reduced glucose uptake in muscle/adipose
Management
Daily single-dose AM steroids → manage with BD or TID lunchtime/evening insulin (not just basal)
Non-diabetic patients on steroids: screen daily BG; treat if >12 persistently
🍶TPN Glycaemic Management
TPN is a major cause of iatrogenic hyperglycaemia — especially dextrose-containing formulas
Target BG during TPN: 6–10 mmol/L
Regular insulin can be added directly to TPN bag (but adjust daily — not flexible)
Better: run a separate VRIII alongside TPN for flexible dose titration
Monitor BG every 4–6 hours during TPN (more frequently when adjusting)
If TPN suddenly stops — maintain IV 10% glucose to prevent hypoglycaemia from any insulin given
Lipid emulsions in TPN may falsely affect some glucometer readings — confirm with lab if unexpected result
⚠️
When TPN is completed, reduce insulin proportionally. Abrupt cessation of TPN without adjusting insulin = severe hypoglycaemia risk.
GCC Context & Exam Preparation
🌍GCC Diabetes Epidemiology
Country
Prevalence (IDF Atlas 2021)
Kuwait
~15.1%
Saudi Arabia
17.7%
UAE
16.3%
Qatar
~16%
Bahrain
~15%
Global average
~10.5%
The GCC region has some of the highest diabetes prevalence rates globally, driven by rapid urbanisation, sedentary lifestyle, high-GI dietary patterns, and genetic predisposition among Arab populations.
National Strategies
Saudi Vision 2030: NCD targets — reduce diabetes complications; national screening programme
Qatar National Diabetes Strategy: Prevention, early detection, self-management support
UAE Weqaya Programme: Nationwide screening since 2008
Kuwait National Diabetes Programme: T2DM prevention focus
Freezing (<0°C) — insulin forms crystals → denatures → ineffective
Air conditioning on maximum — do not store insulin directly in front of AC unit
Do not store in front compartment of fridge (freezing risk from ice box proximity)
CGM Availability in GCC
FreeStyle Libre: available in Saudi, UAE, Qatar, Kuwait, Bahrain — partially NPHIES/insurance funded in SA
Dexcom G6/G7: available through private pharmacy in UAE/Saudi
CGM not yet universally funded by government insurance across all GCC nations (evolving)
GCC Exam Preparation — MCQs
DHA · MOH UAE · SCFHS · QCHP / Prometric style questions. Click "Show Answer" to reveal the explanation.
Q1. A nurse is performing capillary blood glucose monitoring. Which of the following actions is most likely to produce an inaccurate (falsely LOW) result?
A. Using the lateral aspect of the finger pulp
B. Discarding the first drop of blood
C. Squeezing/milking the finger to obtain the sample
D. Warming the hands before testing
Answer: C — Squeezing/milking the finger. This dilutes the blood sample with interstitial fluid, which has a lower glucose concentration, producing a falsely low result. The other options represent correct technique: lateral pulp is correct site, discarding the first drop removes tissue fluid contamination, and warming hands improves blood flow for adequate sampling.
Q2. A T1DM patient is admitted for elective surgery scheduled for 8 am. They usually take insulin glargine (Lantus) 22 units at 10 pm and NovoRapid with meals. What is the most appropriate perioperative insulin management for the night before and morning of surgery?
A. Omit all insulin doses until the patient is eating post-operatively
B. Give usual glargine dose at 10 pm; omit morning NovoRapid
C. Give half the glargine dose (11 units) at 10 pm; omit morning NovoRapid; start VRIII if NBM >2 hours
D. Continue all insulin as normal and increase IV fluids
Answer: C — Half basal dose + omit bolus + VRIII if prolonged NBM. In T1DM, basal insulin must NEVER be completely omitted (DKA risk even at normal BG). The JBDS perioperative guidelines recommend reducing long-acting insulin by approximately 20–50% the night before/morning of surgery. NovoRapid is omitted as the patient is NBM. If NBM for more than one missed meal or BG is uncontrolled, VRIII should be commenced. Option A is dangerous — T1DM without any insulin will develop DKA.
Q3. An unconscious patient with T2DM is found with a blood glucose of 1.8 mmol/L. IV access is in place. Which is the most appropriate immediate treatment?
A. IM glucagon 1mg
B. 75 mL of 20% dextrose intravenously
C. 50 mL of 50% dextrose intravenously
D. Glucogel applied to the buccal mucosa
Answer: B — 75 mL of 20% dextrose IV. This is the preferred inpatient treatment for severe hypoglycaemia with IV access. 50% dextrose (Option C) is associated with serious risk of tissue necrosis on extravasation and is no longer recommended in most UK/international guidelines. IM glucagon (A) is used when IV access is unavailable. Glucogel (D) is contraindicated in unconscious patients due to aspiration risk. Recheck BG in 15 minutes and repeat treatment if <4.0 mmol/L.
Q4. A Muslim patient with T2DM (HbA1c 68 mmol/mol, on glargine 30 units nocte and metformin) asks about fasting during Ramadan. Which risk category does this patient fall into according to JBDS/IDF-DAR Ramadan risk stratification?
A. Low risk — safe to fast without modification
B. Moderate risk — pre-Ramadan education and dose adjustment recommended
C. High risk — medical counselling strongly advised; consider not fasting
D. Very high risk — medical exemption recommended
Answer: C — High risk. This patient has T2DM on insulin (glargine) with suboptimal glycaemic control (HbA1c 68 mmol/mol = 8.4%). Insulin use + HbA1c >58 mmol/mol places this patient in the HIGH risk category. They should receive medical counselling and education about fasting risks. If they choose to fast (their religious right), they require: dose adjustment (shift glargine to Iftar time, reduce by 15–30%), self-monitoring plan (BG checks before and after meals), clear rules about when to break fast (BG <3.9 or >16.7 mmol/L), and close follow-up. Metformin should be moved to Iftar and Suhoor split doses.
Q5. A patient is prescribed a VRIII (variable rate intravenous insulin infusion). Which concurrent intravenous fluid is ESSENTIAL to run alongside the insulin infusion?
A. 0.9% sodium chloride (normal saline) at 125 mL/hr
B. 10% glucose + 0.18% sodium chloride + 20 mmol potassium chloride at 125 mL/hr
C. Hartmann's solution (compound sodium lactate) at 83 mL/hr
D. No concurrent fluid is required — insulin infusion alone is sufficient
Answer: B — 10% glucose + 0.18% NaCl + 20 mmol KCl at 125 mL/hr. This substrate solution serves three critical functions: (1) the 10% glucose provides a glucose substrate to prevent hypoglycaemia from the insulin infusion; (2) the 0.18% NaCl provides maintenance sodium; (3) the 20 mmol KCl is mandatory because insulin drives potassium into cells, causing potentially fatal hypokalaemia. Electrolytes (especially K⁺) must be monitored every 4–6 hours during VRIII. Normal saline (A) contains no glucose — would not prevent hypoglycaemia. VRIII without substrate solution (D) is a serious medication safety error.
Clinical reference guide — Always follow local hospital protocols and seek senior clinical guidance for individual patient management. Not a substitute for clinical judgement.